Brand Name | Status | Last Update |
---|---|---|
fluorodopa | New Drug Application | 2021-01-15 |
Expiration | Code | ||
---|---|---|---|
FLUORODOPA F-18, FLUORODOPA F18, FEINSTEIN | |||
2024-10-10 | NCE, W |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Prostatic neoplasms | D011471 | — | C61 | 2 | 5 | 3 | 2 | 2 | 13 |
Castration-resistant prostatic neoplasms | D064129 | — | — | — | 1 | — | 2 | — | 3 |
Adenocarcinoma | D000230 | — | — | — | — | 1 | 1 | 1 | 3 |
Hypersensitivity | D006967 | EFO_0003785 | T78.40 | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Recurrence | D012008 | — | — | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Neoplasms | D009369 | — | C80 | — | 1 | — | — | — | 1 |
Urogenital neoplasms | D014565 | EFO_0003863 | D07 | — | 1 | — | — | — | 1 |
Neoplasms by site | D009371 | — | — | — | 1 | — | — | — | 1 |
Male genital diseases | D005832 | EFO_0009555 | N50.9 | — | 1 | — | — | — | 1 |
Prostatic diseases | D011469 | — | N42.9 | — | 1 | — | — | — | 1 |
Male genital neoplasms | D005834 | — | — | — | 1 | — | — | — | 1 |
Genital diseases | D000091662 | — | — | — | 1 | — | — | — | 1 |
Drug common name | Fluorodopa f 18 |
INN | fluorodopa (18f) |
Description | 6-((18)F)fluoro-L-dopa is a 6-fluoro-L-dopa and a (18)F radiopharmaceutical. |
Classification | Small molecule |
Drug class | dopamine receptor agonists |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | N[C@@H](Cc1cc(O)c(O)cc1[18F])C(=O)O |
PDB | — |
CAS-ID | 92812-82-3 |
RxCUI | — |
ChEMBL ID | CHEMBL3400972 |
ChEBI ID | 49166 |
PubChem CID | 56494 |
DrugBank | DB13848 |
UNII ID | 2C598205QX (ChemIDplus, GSRS) |